MAFLD
15
4
5
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
7%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (15)
Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease (GL-MAFLD-NRF2 Study)
RE and Probiotics in MAFLD/NAFLD
The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD
Incidence of Liver Disease-Related Outcomes in People With HIV
Frequency of MAFLD and Its Association With Nutritional Status and Metabolic Risk Factors in a Rural Population of Bangladesh
Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.
AI Models vs Non-Invasive Fibrosis Scores in MAFLD Diagnosis
Semaglutide Effectiveness in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease in the Real World Practice
Metabolic Dysfunction-Associated Fatty Liver Disease Impairs Intraoperative Indocyanine Green Fluorescence Cholangiography Quality: Development and Validation of a Predictive Model
Comparison of a Handheld Elastography Device With iLivTouch in Chronic Liver Disease Patients
A Multicenter, Randomized, Crossover Clinical Trial Study of Digital Intelligence Software in Patients With MAFLD
VALidation of Imaging-based Liver Biomarkers in PEDiatric Patients
Diacerein in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Study on the Treatment of MAFLD With Ganzhixiao Capsules
Glucose Disposal Rate as a Metric for Detection of Metabolic Associated Fatty Liver